Guiding the path of treatment for individual cancer patients

Eutropics’ PraediCare Dx™ platform provides a biomarker technology for accelerating drug discovery and development.

PraediCare Dx™

Eutropics is advancing personalized medicine by providing novel, predictive diagnostic tests that are uniquely accurate in guiding patient cancer treatments.

R

Innovative leading cancer treatment response predictors

R

Demonstrated medical utility in blood cancers

R

CLIA certified tests for Acute Myeloid Leukemia

R

Validated tests for Chronic Lymphocytic Leukemia